Clinical Trial Update: A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC [Phase 1, Phase 2]

View source ↗

Summary

Study investigating safety, tolerability, and antitumor activity of X4P-001 in combination with TNBC in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• X4P-001

Snippet

Sponsor: Abbisko Therapeutics Co, Ltd | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN